Masimo Corporation (MASI)

Masimo Corporation (MASI) Healthcare & Pipeline Overview

Masimo Corporation is a global leader in noninvasive patient monitoring, offering advanced pulse oximetry and hospital automation solutions. Its signal extraction technology and rainbow SET platform differentiate it within the medical devices sector, addressing the limitations of conventional monitoring and expanding into diverse healthcare settings.

What Is the Investment Thesis for MASI?

Masimo Corporation presents a notable research candidate based on its leadership in noninvasive patient monitoring and its expanding portfolio of hospital automation solutions. The company's proprietary SET and rainbow SET technologies provide a competitive edge, driving adoption in hospitals and other healthcare settings. With a market capitalization of $9.42B and a P/E ratio of 123.1, Masimo's valuation reflects its growth potential. Key catalysts include the continued expansion of its hospital automation platform and the introduction of new monitoring technologies. However, investors should be aware of potential risks such as competition from established medical device companies and regulatory hurdles. Masimo's gross margin of 61.7% indicates strong pricing power and efficient operations.

Based on FMP financials and quantitative analysis

MASI Key Highlights

• Market Cap of $9.42B reflects Masimo's significant presence in the medical device industry.
• P/E ratio of 123.1 suggests investors anticipate future earnings growth.
• Gross Margin of 61.7% demonstrates efficient operations and strong pricing power.
• Profit Margin of 4.9% indicates areas for potential improvement in operational efficiency.
• Beta of 1.20 suggests the stock is more volatile than the overall market.

Who Are MASI's Competitors?

MASI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MASI's Key Strengths?

• Proprietary SET and rainbow SET technologies
• Strong brand reputation
• Integrated hospital automation platform
• Extensive distribution network

What Are MASI's Weaknesses?

• High P/E ratio may indicate overvaluation
• Profit margin could be improved
• Reliance on hospital spending
• Competition from established medical device companies

What Could Drive MASI Stock Higher?

• Launch of new monitoring technologies and sensors.
• Expansion of the Hospital Automation platform into new hospitals and healthcare systems.
• Increasing adoption of Masimo's products in emerging markets.
• Strategic partnerships with other healthcare technology companies.

What Are the Key Risks for MASI?

• Rich valuation — a P/E of 123.1 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Insider selling — insiders were net sellers of roughly $843.7M recently.
• Competition from established medical device companies.
• Regulatory hurdles and delays in product approvals.
• Economic downturns and reduced hospital spending.
• Patent expirations and potential for generic competition.
• Supply chain disruptions affecting manufacturing and distribution.

What Are the Growth Opportunities for MASI?

• Expansion of Hospital Automation Platform: Masimo's Hospital Automation platform, including Patient SafetyNet and UniView, offers significant growth potential by integrating patient monitoring data with clinical workflows. The market for hospital automation solutions is projected to reach billions of dollars by 2030, driven by the need to improve patient safety and reduce healthcare costs. Masimo's competitive advantage lies in its ability to seamlessly integrate its monitoring technologies with its automation platform, providing a comprehensive solution for hospitals.
• Penetration of Emerging Markets: Emerging markets represent a significant growth opportunity for Masimo, as healthcare systems in these regions increasingly adopt advanced patient monitoring technologies. The demand for noninvasive monitoring solutions is growing in countries with expanding healthcare infrastructure and rising healthcare expenditure. Masimo can leverage its existing distribution network and OEM partnerships to penetrate these markets and establish a strong presence.
• Development of New Monitoring Technologies: Masimo's commitment to innovation drives the development of new monitoring technologies that address unmet clinical needs. The company's research and development efforts focus on expanding the capabilities of its rainbow SET platform and exploring new applications for its SedLine brain function monitoring technology. The introduction of new monitoring parameters and solutions can drive revenue growth and strengthen Masimo's competitive position.
• Expansion into Consumer Healthcare: Masimo's e-commerce site, masimopersonalhealth.com, provides a platform for expanding into the consumer healthcare market. The demand for personal health monitoring devices is growing, driven by increasing awareness of preventive healthcare and the availability of user-friendly technologies. Masimo can leverage its expertise in noninvasive monitoring to develop and market consumer-focused products, such as wearable pulse oximeters and sleep monitors.
• Strategic Acquisitions and Partnerships: Masimo can pursue strategic acquisitions and partnerships to expand its product portfolio, enter new markets, and enhance its technological capabilities. Acquisitions of companies with complementary technologies or established market positions can accelerate Masimo's growth and strengthen its competitive advantage. Partnerships with healthcare providers and technology companies can facilitate the integration of Masimo's solutions into clinical workflows and expand its reach.

What Opportunities Does MASI Have?

• Expansion into emerging markets
• Development of new monitoring technologies
• Expansion into consumer healthcare
• Strategic acquisitions and partnerships

What Threats Does MASI Face?

• Competition from established medical device companies
• Regulatory hurdles
• Patent expirations
• Economic downturns

What Are MASI's Competitive Advantages?

• Proprietary Masimo SET and rainbow SET technologies provide a competitive advantage in pulse oximetry.
• Strong brand reputation for accuracy and reliability in patient monitoring.
• Extensive patent portfolio protects its core technologies.
• Integrated hospital automation platform enhances customer value and creates switching costs.
• Established distribution network and OEM partnerships provide broad market access.

What Does MASI Do?

Masimo Corporation, founded in 1989 and headquartered in Irvine, California, is a global medical technology company that develops, manufactures, and markets a range of noninvasive patient monitoring technologies and hospital automation solutions. The company's core innovation lies in its Masimo Signal Extraction Technology (SET) pulse oximetry, designed to overcome the limitations of conventional pulse oximetry by accurately measuring oxygen saturation even during patient motion and low perfusion. This technology forms the basis of many of Masimo's products, which are used in hospitals, emergency medical services, home care, and other healthcare settings. Masimo's product portfolio includes the rainbow SET platform, which expands on the capabilities of SET by noninvasively monitoring multiple hemoglobin parameters, including oxygen saturation, pulse rate, perfusion index, and respiration rate. This platform also enables the monitoring of hemoglobin concentration, carboxyhemoglobin, and methemoglobin. Beyond pulse oximetry, Masimo offers SedLine brain function monitoring technology, capnography and gas monitoring products, O3 regional oximetry for tissue oxygen saturation measurement, and hemodynamic monitoring solutions. The company's Masimo Hospital Automation platform integrates these monitoring technologies with patient surveillance and data management systems, such as Patient SafetyNet and UniView, to improve patient safety and clinical workflows. Masimo distributes its products through a direct sales force, distributors, and original equipment manufacturer (OEM) partners, reaching a diverse customer base across the healthcare spectrum. The company also sells non-medical/consumer products through its e-commerce site, masimopersonalhealth.com.

What Products and Services Does MASI Offer?

• Develops and markets noninvasive patient monitoring technologies.
• Offers Masimo SET pulse oximetry for accurate oxygen saturation measurement.
• Provides Masimo rainbow SET platform for monitoring multiple hemoglobin parameters.
• Offers SedLine brain function monitoring technology.
• Develops capnography and gas monitoring products.
• Provides O3 regional oximetry for tissue oxygen saturation measurement.
• Offers hemodynamic monitoring solutions.
• Develops and markets hospital automation platforms.

How Does MASI Make Money?

• Sells noninvasive patient monitoring devices and sensors.
• Generates revenue from the sale of hospital automation software and services.
• Partners with original equipment manufacturers (OEMs) to integrate its technologies into their products.
• Distributes products through a direct sales force and distributors.
• Sells non-medical/consumer products through its e-commerce site.

What Industry Does MASI Operate In?

Masimo Corporation operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced patient monitoring technologies. The global market for patient monitoring devices is expected to grow, driven by factors such as an aging population, rising prevalence of chronic diseases, and increasing adoption of remote patient monitoring solutions. Masimo competes with established medical device companies, such as Baxter International Inc. (BAX), as well as specialized players in specific monitoring segments. The company's focus on noninvasive technologies and its integrated hospital automation platform position it to capitalize on the growing demand for patient safety and improved clinical workflows.

Who Are MASI's Key Customers?

• Hospitals and acute care facilities
• Emergency medical service providers
• Home care providers
• Long-term care facilities
• Physician offices
• Veterinarians
• Consumers

Net sellingInsider Activity

Over the past six months, Masimo Corporation insiders filed 30 SEC Form 4 transactions — 30 sales and 0 purchases. On net that is roughly 4.9M shares disposed (about $843.7M), a signal worth weighing alongside the fundamentals.

FY2027 estForward Outlook

Wall Street analysts project Masimo Corporation revenue of about $1.63B for fiscal 2027, with EPS near $6.00.

F-Score 8/9Financial Health

Masimo Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 9.77 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 9%Key Financial Metrics

Return on equity for Masimo Corporation stands at 9.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.6%, showing how much profit it generates from its asset base. MASI trades at a trailing price-to-earnings ratio of 123.11, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.8%, the inverse of the P/E and a quick read on earnings relative to price.

Masimo Corporation (MASI) Valuation Context

Valued at $9.42B, MASI is classified as a mid-cap stock. Relative to its peer group, MASI's quantitative score of 55/100 is below the peer average of 71/100.

Company Profile

Masimo Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Catherine Szyman. MASI has traded publicly since 2007.

MASI Financials

MASI Latest News

MASI Analyst Consensus

MASI MoonshotScore

MASI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources